234
Views
7
CrossRef citations to date
0
Altmetric
Article

Efficacy of intratympanic corticosteroid, intravenous batroxobin and combined treatment for sudden sensorineural hearing loss with type-2 diabetes

, , , , , , & show all
Pages 522-528 | Received 03 Dec 2018, Accepted 05 Mar 2019, Published online: 22 Apr 2019
 

Abstract

Background: Intratympanic corticosteroid (IC), intravenous batroxobin (IB) as the treatment for sudden sensorineural hearing loss (SSNHL) has been reported. However, the data on combination therapy (CT) was scarce.

Objective: The aim of this retrospective study was to compare the efficacy of IC, IB, and CT in the treatment of SSNHL with diabetes.

Material and Methods: A total of 212 SSNHL patients with diabetes, who were initially treated within 14 days of onset of disease, were divided into three groups by treatment modality. The hearing recovery was evaluated by the results of pure-tone test after completion of treatment. The prognostic factors, including age, severity of initial hearing loss, duration to onset of treatment, and audiometric curve type, were further compared.

Results: There was a significant difference in hearing recovery by the treatment (p < .05). Recovery rates in the CT group were significantly higher in patients with early treatment than with delayed treatment (p = .021). However, duration and recovery rate was not significantly correlated in IC and IB group (p > .05). In patients recieving early treatment, the recovery rate in CT group was significantly higher than that in IC (p = .013) and IB group (p = .029). Regardless of treatment, the recovery rates were higher in patients with flat and ascending audiograms (p < .05).

Conclusions and Significance: Patients receiving combined therapy, especially in the early stage of SSNHL, could achieve significantly superior recovery in the treatment of SSNHL with diabetes, compared with those using IC or IB alone.

Chinese abstract

背景:已有关于鼓室内皮质类固醇(IC)和静脉注射巴曲酶(IB)作为突发性感音神经性听力损失(SSNHL)的治疗方法的报道。然而, 关于联合治疗(CT)的资料很少。

目的:本回顾性研究的目的是比较IC、IB和CT治疗患糖尿病的SSNHL的疗效。

材料和方法:共212例SSNHL糖尿病患者, 在疾病发作后14天内接受首次治疗。按治疗方式分为3组。在完成治疗后根据纯音测试的结果评估听力恢复。进一步比较预后因素, 包括年龄、初始听力损失的严重程度、治疗开始的持续时间和听力曲线类型。

结果:治疗后听力恢复有显著差异(p <.05)。早期治疗组患者CT组恢复率明显高于迟缓治疗组(p = .021)。然而, IC和IB组的持续时间和恢复率无显著相关性(p> .05)。在接受早期治疗的患者中, CT组的恢复率显著高于IC组(p = .013)和IB组(p = .029)。无论什么治疗, 平坦和上升的听力图的患者的恢复率更高(p <.05)。

结论和意义:与仅使用IC或IB的患者相比, 接受联合治疗的患者, 特别是处于SSNHL的早期阶段, 可以在治疗糖尿病SSNHL方面取得明显优势的康复效果。

Acknowledgments

With exception of data collection, preparation of this paper including design and planning was supported by the Beijing Anzhen Hospital and the Statistical Analysis Laboratory.

Disclosure statement

The authors declared that there are no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Additional information

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article. This research was funded by Project of development funds of Beijing traditional Chinese medicine science and technology under Grant JJ2015-07.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 226.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.